The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

Receptor desensitisation as a tolerance hypothesis, and its weak evidence

This is a generated summary. It shows the 8 most-liked posts from a topic of 58, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
OV
o.vukovicTL2 Moderator23 May 2026#3

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

25 likes 2mo
FN
f.novakTL2 Moderator19 Jun 2026#22

Pharmacological class effects: all GLP-1 agonists slow gastric emptying and suppress appetite. Those are class effects, not unique to one compound. Effects that differ between compounds are usually about potency or receptor selectivity.

26 likes 1mo
WV
w.verhoevenTL2 Moderator30 Jun 2026#31

Species differences: rodent studies show the same compounds produce effects in rodents that predict human effects reasonably well for semaglutide and tirzepatide. The track record is less clear for novel compounds with less human data.

28 likes 28d
WP
weekly_pinTL2Regular10 Jul 2026#40

Cross-reactivity and selectivity: the compounds are not perfectly selective for their target receptors. Semaglutide has some activity on other receptors; tirzepatide activates both GLP-1 and GIP with different affinities. The off-target effects are part of the overall pharmacology.

29 likes 18d
SK
s.karlsen_rphTL3Pharmacist12 Jul 2026#42

post #41 answers the question as asked. The question underneath it is different.

Amylin receptor signalling: amylin promotes satiety and slows gastric emptying through a receptor distinct from GLP-1. The hypothesis behind combination therapy is two complementary satiety mechanisms.

21 likes 16d
CV
c.vasquezTL2 Moderator15 Jul 2026#45

GLP-1 receptor signalling: the GLP-1 receptor is expressed on beta cells (insulin secretion), on neurons (appetite and gastric motility), and on myocardium (contractility). Different tissues respond to the same signal in different ways.

30 likes 13d
CC
c.correiaTL2 Moderator19 Jul 2026#49

Bias and desensitisation: receptors can be biased (preferentially activating some downstream pathways over others) and can desensitise over time (responding less to the same stimulus with repeated exposure). Both might affect long-term response to these compounds.

22 likes 9d
NS
n.szaboTL2 Moderator24 Jul 2026#54

Glucagon receptor agonism: glucagon receptor agonism increases energy expenditure and promotes hepatic fat oxidation. The mechanism is distinct from GLP-1 and GIP agonism and the clinical consequences are still being characterised.

23 likes 4d

Read the full topic (58 posts)

Suggested topics

TopicParticipantsRepliesViewsActivity
Biased agonism: a real phenomenon, an over-used explanation — what changed since
Biased agonism: a real phenomenon, an over-used explanation — what changed since — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I…
EKJHROKFEK+49 56 47k 17mo
Follow-up: Glucagon receptor agonism in a weight-loss compound
Glucagon receptor agonism in a weight-loss compound Writing it up because I had to work it out twice and would rather nobody else did. I would like to understand what this number means before I repeat it…
AMHNDNLAMD+5 9 21k 7mo
GLP-1 receptor distribution: central and peripheral
Posting this under the heading it deserves: GLP-1 receptor distribution: central and peripheral Everything below is what sits behind that. A documentation question rather than an analytical one. I have a…
KHBPJNNSNH+90 98 30k 22h
Why appetite effects are mostly central
Why appetite effects are mostly central I have a specific reason for asking rather than idle curiosity, and the context is below. Posting the method first, because I know what the first three replies will…
EKHFSB 2 56k 16mo
Vagal afferents and the gut-brain pathway
On the subject in the title: Vagal afferents and the gut-brain pathway Working notes rather than a conclusion. A documentation question rather than an analytical one. I have a certificate in front of me that…
KRBSKSBCD+5 9 44k 13mo

Related topics — sharing the tags tirzepatide, retatrutide, amylin analogues

TopicParticipantsRepliesViewsActivity
Semaglutide formulation: what is in the licensed product besides the peptide
Semaglutide formulation: what is in the licensed product besides the peptide — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SURMOUNT-1 ( N…
VSNTEKSPEK+29 35 4.4k 1h
Follow-up: Semaglutide versus liraglutide head to head: reading STEP 8 carefully
Semaglutide versus liraglutide head to head: reading STEP 8 carefully — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim…
DYKBFHKVM+1 5 11k 20mo
Second pass at: Semaglutide and alcohol: what is actually documented
Second pass at: Semaglutide and alcohol: what is actually documented Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in…
IBDNOFID+15 19 4.4k 13mo
Why cagrilintide alone is discussed so much less than in combination
Why cagrilintide alone is discussed so much less than in combination I have a specific reason for asking rather than idle curiosity, and the context is below. Session topic: SURMOUNT-OSA ( N Engl J Med ,…
MENVRFCHKB+93 108 35k 16mo
Peak-to-trough ratio at steady state for a weekly agent
On the subject in the title: Peak-to-trough ratio at steady state for a weekly agent Working notes rather than a conclusion. I would like to understand what this number means before I repeat it anywhere. A…
SMVNICPAJH+58 64 9.7k 2mo